Intra-articular injection of hyaluronate and indomethacin in rabbits with antigen-induced arthritis

Rheumatology International

Volumn 27, Issue 12, 2007, Pages 1099-1111

  Lo, Yow Jen ^a   Sheu, Ming Thau ^a   Tsai, Wen Chi ^b   Lin, Yun Ho ^a   Li, Jau Le ^c   Liang, Yu Chih ^a   Chang, Chi Ching ^c   Hsieh, Ming Shium ^c   Chen, Chien Ho ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b MIN SHENG GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antigen induced arthritis; CRP; Hyaluronate; Indomethacin; MMP; PGE2

Indexed keywords

ARTZDISPO; C REACTIVE PROTEIN; HYALURONIC ACID; INDOMETACIN; OVALBUMIN; PROSTAGLANDIN E2; PROTEOGLYCAN; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HISTOLOGY; HYPERPLASIA; JOINT SWELLING; MONOTHERAPY; NONHUMAN; PANNUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RABBIT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; C-REACTIVE PROTEIN; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HINDLIMB; HYALURONIC ACID; INDOMETHACIN; INJECTIONS, INTRA-ARTICULAR; JOINTS; MATRIX METALLOPROTEINASE 3; STIFLE; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 34548489383     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0346-1     Document Type: Article

References (48)

1. Walker JM, Helewa A (1996) Physical therapy in arthritis. Saunders, Philadelphia
2. Shahbaz H, James WS (2001) Septic arthritis. Curr Treat Opt Infect Dis 3:279-286
3. Goldring SR, Gravallese EM (2000) Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2:33-37
4. Brandt KD, Smith GN Jr, Simon LS (2000) Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: what is the evidence? Arthritis Rheum 43:1192-1203
5. Ceponis A, Waris E, Monkkonen J, Laasonen L, Hyttinen M, Solovieva SA, Hanemaaijer R, Bitsch A, Konttinen YT (2001) Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in established antigen-induced arthritis in rabbits. Arthritis & Rheum 44:1908-1916
6. Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A (2003) Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther 5:R122-R131
7. Moreland LW (2003) Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 5:54-67
8. Aggarwal A, Sempowski IP (2004) Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature Can Fam Physician 50:249-256
9. Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T (1992) The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin E2 production in human osteoarthritic synovial cells. Agents Actions 37:155-156
10. Tobetto K, Yasui T, Ando T, Hayaishi M, Motohashi N, Shinogi M, Mori I (1992) Inhibitory effects of hyaluronan on [14C] arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol 60:79-84
11. Larsen NE, Lombard KM, Parent EG, Balazs EA (1992) Effect of hylan on cartilage and chondrocyte cultures. J Orthop Res 10:23-32
12. .) radicals is dependent on hyaluronan molecular mass. Cell Biochem Funct 12:281-288
13. Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C (2004) Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum 50:314-326
14. Roth A, Mollenhauer J, Wagner A, Fuhrmann R, Straub A, Venbrocks RA, Petrow P, Bräuer R, Schubert H, Ozegowski J, Peschel G, Müller PJ, Kinne RW (2005) Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis. Arthritis Res Ther 7:R677-R686
15. Williams HJ, Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, Field EH, Skosey JL, Alarcon GS, Paulus HE, Russell IJ, Sharp JT (1993) Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis & Rheum 36:1196-1206
16. Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63:901-907
17. Wolfe F, Zhao S, Lane N (2000) Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43:378-385
18. Huang SH (2000) Rheumatology: 7. Basics of therapy. CMAJ 163:417-423
19. Yoon JB, Kim SJ, Hwang SG, Chang S, Kang SS, Chun JS (2003) Non-steroidal anti-inflammatory drugs inhibit nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes independent of cyclooxygenase activity. J Biol Chem 278:15319-15325
20. Dawson J, Engelhardt P, Kastelic T, Cheneval D, MacKenzie A, Ramage P (1999) Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment. Rheumatology (Oxford) 38:401-406
21. Shafer-Weaver KA, Sayers T, Kuhnd DB, Strobl SL, Burkett MW, Baseler M, Malyguine A (2004) Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med 2:31
22. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA (1996) Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem 271:695-701
23. Ribbens C, Porras M, Martin Y, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161-166
24. Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA, van Rijswijk MH (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology 38(11):1081-1087
25. Atkinson JP (2001) C-Reactive protein: a Rheumatologist's friend revisited. Arthritis Rheum 44:995-996
26. Weinhold B, Bader A, Poli V, Ruther U (1997) Interleukin-6 is necessary, but not sufficient, for induction of the human C-reactive protein gene in vivo. Biochem J 325:617-621
27. 2 mediates growth arrest in NFS-60 cells by down-regulating interleukin-6 receptor expression. Biochem J 370:315-321
28. Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE (2005) Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. Ann Rheum Dis 64:1003-1008
29. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852-858
30. Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA, van Rijswijk MH (1999) Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford) 38:1081-1087
31. Catrina AI, Lampa J, Ernestam S, af Klint E, Bratt J, Klareskog L, Ulfgren AK (2002) Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) 41:484-489
32. Vincenti MP, Clark IM, Brinckerhoff CE (1994) Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 37:1115-1126
33. Cawston T (1998) Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today 4:130-137
34. Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13:228-233
35. Ribbens C, Andre B, Jaspar JM, Kaye O, Kaiser MJ, De Groote D, Malaise MG (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatology 27:888-893
36. Taylor DJ, Cheung NT, Dawes PT (1994) Increased serum proMMP-3 in inflammatory arthritis: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 53:768-772
37. Han F, Ishiguro N, Ito T, Sakai T, Iwata H (1999) Effects of sodium hyaluronate on experimental osteoarthritis in rabbit knee joints. Nagoya J Med Sci 62:115-126
38. Takahashi K, Goomer RS, Harwood F, Kubo T, Hirasawa Y, Amiel D (1999) The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1beta(IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 7:182-190
39. Qiu B, Liu SQ, Peng H, Wang HB (2005) The effects of sodium hyaluronate on mRNA expressions of matrix metalloproteinase-1, -3 and tissue inhibitor of metalloproteinase-1 in cartilage and synovium of traumatic osteoarthritis model. Chin J Traumatol 8:8-12
40. Sasaki A, Sasaki K, Konttinen YT, Santavirta S, Takahara M, Takei H, Ogino T, Takagi M (2004) Hyaluronate inhibits the interleukin-1beta-induced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells. Tohoku J Exp Med 204:99-107
41. Monfort J, Nacher M, Montell E, Vila J, Verges J, Benito P (2005) Chondroitin sulfate and hyaluronic acid (500-730 kDa) inhibit stromelysin-1 synthesis in human osteoarthritic chondrocytes. Drugs Exp Clin Res 31:71-76
42. Sadowski T, Steinmeyer J (2001) Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis & Cartilage 9:407-415
43. Yamada H, Kikuchi T, Nemoto O, Obata K, Sato H, Seiki M, Shinmei M (1996) Effects of indomethacin on the production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by human articular chondrocytes. J Rheumatol 23:1739-1743
44. Bevilacqua M, Devogelaer JP, Righini V, Famaey JP, Manicourt DH (2004) Effect of nimesulide on the serum levels of hyaluronan and stromelysin-1 in patients with osteoarthritis: a pilot study. Int J Clin Pract Suppl 144:13-19
45. Yan M, Noguchi K, Ruwanpura SM, Ishikawa I (2005) Cyclooxygenase-2- dependent prostaglandin (PG) E2 downregulates matrix metalloproteinase-3 production via EP2/EP4 subtypes of PGE2 receptors in human periodontal ligament cells stimulated with interleukin-1alpha. J Periodontology 76:929-935
46. Calabrese LH, Michel BA, Bloch DA, Arend WP, Edworthy SM, Fauci AS, Fries JF, Hunder GG, Leavitt RY, Lie JT, Lightfoot RW, Masi AT, McShave DJ, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ (1990) The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis & Rheum 33:1108-1113
47. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M (1997) Reduction of serum matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-α (cA2) therapy. Br J Rheumatol 36:643-650
48. Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen JS (1998) Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 25:105-110